Benzinga | Jun 3, 2021 08:06AM EDT

Hoth Therapeutics To Present Data On Preclinical Results For Its HT-KIT For mRNA Frame-Shifting On Jun. 3 at 1 p.m. EDT

Shareholder Presentation Today to Further Highlight Results

HT- KIT Reduces KIT expression and induces apoptosis of neoplastic human mast cells

Inhibits tumor growth in humanized xenograft mast cell neoplasia models

Reduces liver infiltration of neoplastic mast cells

Reduces tumor growth in isograft models of mast cell neoplasia

Reduces signs of mast cell leukemia in an isograft model of mutant mast cell neoplasia

NEW YORK, June 3, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that it will share positive results from a preclinical trial during its shareholder presentation, reinforcing the potential of HT-KIT, a new molecular entity under development for treatment of mast cell-derived cancers and anaphylaxis.



HT-KIT is an mRNA frame-shifting therapeutic designed to specifically target the receptor tyrosine kinase KIT, which is required for the proliferation, survival and differentiation of bone marrow-derived hematopoietic stem cells. Mutations in the KIT pathway have been associated with several human cancers, such as mast cell-derived cancers, systemic mastocytosis with associated hematologic neoplasm, or mast cell leukemia, gastrointestinal stromal tumors, and acute myeloid leukemia.

The preclinical animal trials were conducted using humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers, such as mast cell leukemia and mast cell sarcoma. Key findings of the mouse models found that HT-KIT:

* Reduces KIT expression and induces apoptosis of neoplastic human mast cells

* Inhibits tumor growth in humanized xenograft mast cell neoplasia models

* Reduces liver infiltration of neoplastic mast cells

* Reduces tumor growth in isograft models of mast cell neoplasia

* Reduces signs of mast cell leukemia in an isograft model of mutant mast cell neoplasia

"The results from our HT-KIT preclinical trial further reinforces our belief that targeting mutations in the KIT pathway could be the answer for patients living with mast cell-derived cancers and related conditions," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Our team looks forward to sharing the data that support our findings in greater detail with our shareholders at the presentation on June 3rd."

The data presentation is open to all shareholders and any parties interested in learning more. Any questions for Hoth Therapeutics and presenters, Dr. Cruse and Dr. Johns can be submitted in advance of the presentation by emailing questions to investorrelations@hoththerapeutics.com.

Meeting Details:

Date: Jun 3, 2021

Time: 1:00 PM ET

To receive the Zoom meeting details, please click the attached link to register for the event.

https://zoom.us/meeting/register/tJIsc-2uqDktEtJQUD7CrJjzUKJQWSAen7yH

After registering, you will receive a confirmation email containing information about joining the meeting.

Data will also be available for review at the company's 2021 ASCO Annual Meeting exhibit.